Research
Genitourinary (GU) cancers represent a diverse and complex group of diseases that require innovative approaches to understand their progression and develop effective treatments. Our lab is pioneering precision oncology through advanced 3D-bioprinted tumoroid models that faithfully replicate the tumor microenvironment across bladder, prostate, and other GU malignancies. By integrating environmental, metabolic, and immune insights with patient-derived biology, we aim to uncover new therapeutic vulnerabilities and accelerate the translation of laboratory discoveries into clinical impact.
We are currently leading four major research initiatives, described below:
We develop next-generation 3D-bioprinted tumoroid models that replicate patient tumors to study treatment response and guide precision oncology.
We investigate bioactive small molecules derived from natural sources, such as nimbolide, to uncover new mechanisms of tumor suppression and immune modulation.
Our work explores how the mitochondrial regulator ANGEL2 drives metabolic stress, immune evasion, and therapy resistance across genitourinary cancers.
We study how environmental toxins, including pesticides and wildfire smoke, reshape tumor biology and contribute to cancer initiation and progression.
